TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock Rated “Hold” by Wall Street Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have received a consensus recommendation of “Hold” from the five brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $10.20.

A number of analysts have commented on the stock. HC Wainwright upped their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, September 23rd. Stifel Nicolaus set a $12.00 price objective on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Zacks Research upgraded TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Finally, Guggenheim set a $12.00 target price on TriSalus Life Sciences in a research note on Wednesday, September 23rd.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC boosted its holdings in shares of TriSalus Life Sciences by 29.3% during the 2nd quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company’s stock worth $29,814,000 after buying an additional 1,485,664 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $12,099,000. Nantahala Capital Management LLC bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at $4,550,000. State Street Corp increased its stake in shares of TriSalus Life Sciences by 86.3% in the 2nd quarter. State Street Corp now owns 610,963 shares of the company’s stock valued at $2,780,000 after acquiring an additional 282,943 shares in the last quarter. Finally, Empire Financial Management Company LLC increased its stake in shares of TriSalus Life Sciences by 316.9% in the 1st quarter. Empire Financial Management Company LLC now owns 300,275 shares of the company’s stock valued at $1,201,000 after acquiring an additional 228,248 shares in the last quarter. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences Stock Performance

TriSalus Life Sciences stock opened at $3.63 on Thursday. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. TriSalus Life Sciences has a 52-week low of $2.20 and a 52-week high of $7.95. The firm has a 50 day moving average price of $4.40 and a two-hundred day moving average price of $4.41.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $11.41 million for the quarter, compared to analyst estimates of $10.27 million. As a group, equities research analysts forecast that TriSalus Life Sciences will post -0.53 EPS for the current year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.